Market Spotlight: Mantle Cell Lymphoma

Figure 1: Global trends in incident cases of MCL, 2017–26
Figure 2: Global incident cases of MCL, by age, 2017
Figure 3: Overview of pipeline drugs for MCL in the US
Figure 4: Pipeline drugs for MCL, by company
Figure 5: Pipeline drugs for MCL, by drug type
Figure 6: Pipeline drugs for MCL, by classification
Figure 7: Cirmtuzumab for MCL (December 7, 2020): Phase Ib/II - CIRLL Study
Figure 8: Breyanzi for MCL (December 5, 2020): Phase I - TRANSCEND
Figure 9: Pirtobrutinib for MCL (December 5, 2020): Phase I/II - BRUIN
Figure 10: Tecartus for MCL (December 9, 2019): Phase II - ZUMA-2 (r/r MCL)
Figure 11: Key upcoming events in MCL
Figure 12: Probability of success in the hematologic pipeline
Figure 13: Clinical trials in MCL
Figure 14: Top 10 drugs for clinical trials in MCL
Figure 15: Top 10 companies for clinical trials in MCL
Figure 16: Trial locations in MCL
Figure 17: MCL trials status
Figure 18: MCL trials sponsors, by phase

Table 1: Global incident cases of MCL, 2017–26
Table 2: Global incident cases of MCL, by gender, 2017
Table 3: Marketed drugs for MCL
Table 4: Pipeline drugs for MCL in the US
Table 5: Cirmtuzumab for MCL (December 7, 2020)
Table 6: Parsaclisib for MCL (December 6, 2020)
Table 7: Breyanzi for MCL (December 5, 2020)
Table 8: Pirtobrutinib for MCL (December 5, 2020)
Table 9: Tecartus for MCL (December 9, 2019)
Table 10: Pirtobrutinib for MCL (December 8, 2019)
Table 11: Historical global sales, by drug ($m), 2016–20
Table 12: Forecasted global sales, by drug ($m), 2021–25